Utilization of relative evaluation of pancreatic perfusion CT parameters to support appropriate pancreatic adenocarcinoma diagnosis
Pancreatology · 2024
DOI: 10.1016/j.pan.2024.11.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2024. Verfasst von Yoshihiro Konno und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan. Electronic a…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Tomography, X-Ray Computed. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
OBJECTIVES: To investigate the effect of relative evaluation of perfusion computed tomography (PCT) parameters in the diagnosis of pancreatic adenocarcinoma (PAC). METHODS: Of the 117 patients in which PCT was performed (May 2019 to June 2023), 99 patients with mass lesions (MLs), including 50 PAC and 11 patients with mass-forming pancreatitis (MFP), and 15 patients without MLs but with main pancreatic duct (MPD) abnormalities, including 6 PAC and 7 no diagnosis of malignancy (NDM) cases were enrolled in this study. Parameter values were obtained from parametric maps of blood flow (BF), blood volume (BV), and mean transit time (MTT) for the ML and abnormal MPD part (AMP), pancreas and spleen. Diagnostic performance was evaluated based on receiver operating characteristic analysis for absolute values and relative values for pancreas and spleen. RESULTS: BFML, BVML, BFML/Pancreas, BFML/Spleen, BVML/Pancreas and BVML/Spleen were significantly lower in PAC than MFP cases. Areas under the curve (AUCs) for BFML, BFML/Pancreas, BFML/Spleen were 0.71 (sensitivity, 54 %; specificity, 91 %), 0.80 (sensitivity, 74 %; specificity, 82 %) and 0.79 (sensitivity, 68 %; specificity. 91 %), respectively. The AUCs for BVML, BVML/Pancreas, BVML/Spleen were 0.72 (sensitivity, 48 %; specificity, 100 %), 0.85 (sensitivity, 76 %; specificity, 91 %) and 0.87 (sensitivity, 76 %; specificity, 91 %), respectively, with significantly better diagnostic performance on relative evaluation (P < 0.05). BVAMP/Spleen and MTTAMP/Spleen were significantly higher in PAC than NDM cases, with AUCs of 1 (100 % sensitivity and specificity) and 0.91 (sensitivity, 86 %; specificity, 100 %), respectively. CONCLUSIONS: Relative evaluation of PCT parameters is expected to contribute to more appropriate diagnosis of PAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan. Electronic address: hiro.konno@med.id.yamagata-u.ac.jp.
- Department of Diagnostic Radiology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata-shi, Yamagata, 990-9585, Japan.
- Department of Radiology, Okitama Public General Hospital, Japan.
- Department of Gastroenterology, Faculty of Medicine, Yamagata University, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Konno, Y., Takisawa, K., Kanoto, M., Ishii, Y., Obata, Y., Ishizawa, T., Matsuda, A., & Kakizaki, Y. (2024). Utilization of relative evaluation of pancreatic perfusion CT parameters to support appropriate pancreatic adenocarcinoma diagnosis. Pancreatology. https://doi.org/10.1016/j.pan.2024.11.008
Vancouver
Konno Y, Takisawa K, Kanoto M, Ishii Y, Obata Y, Ishizawa T, et al. Utilization of relative evaluation of pancreatic perfusion CT parameters to support appropriate pancreatic adenocarcinoma diagnosis. Pancreatology. 2024. doi:10.1016/j.pan.2024.11.008
BibTeX
@article{Konno2024,
author = {Konno, Yoshihiro and Takisawa, Kazuho and Kanoto, Masafumi and Ishii, Yoshiki and Obata, Yoshie and Ishizawa, Tetsuya and Matsuda, Akiko and Kakizaki, Yasuharu},
title = {Utilization of relative evaluation of pancreatic perfusion CT parameters to support appropriate pancreatic adenocarcinoma diagnosis},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2024.11.008}
}
EUVIMED